Derma Sciences' MEDIHONEY(TM) Proven to Speed Healing in Stalled ...(goand then the launch in the US and Cana...),Health

Date:9/15/2008

go, and then the launch in the US and Canada this year, clinicians have consistently reported that MEDIHONEY is effective on stalled ulcers of various etiologies. The recently published study now provides clear evidence of this by demonstrating results proven in a rigorous randomized controlled study. Clinicians can now feel confident in the value that they place on MEDIHONEY and the role it has to play in an overall treatment strategy.

This is significant for our product as currently, only 50% of chronic wounds heal with first-line treatment options. It is also significant for patients who suffer the effects of notoriously painful leg ulcers, with uncommonly long durations - sometimes lasting years."

Wound care is a major healthcare market with an estimated value of $10 billion in 2007 that is expected to grow to $12.5 billion by 2012. The global growth is being driven by several factors, including an aging population, the rise in the global incidence of diabetes and chronic vascular disorders, and a steady advancement in wound care technologies.

The Journal of Clinical Nursing (JCN) is an international, peer reviewed, scientific journal that seeks to promote the development and exchange of knowledge that is directly relevant to all spheres of nursing practice. The primary aim is to promote a high standard of clinically related scholarship which supports the practice and discipline of nursing. JCN publishes high quality papers on issues related to clinical nursing, regardless of where care is provided. This includes - but is not limited to - ambulatory care, community care, family care, home, hospital, practice, primary and secondary, and public health.

For more information on the Journal of Clinical Nursing, please visit: http://www.blackwellpublishing.com/journal.asp?ref=0962-1067

About Derma Sciences

Derma Sciences is a global manufa
'/>"/>

SOURCE Derma Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved

3 GOOD

Page: 1 2 3
Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
7. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
8. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
9. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
10. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
11. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections